Hims & Hers Health, Inc. (HIMS)
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S.
Why The Hims & Hers Health Rally Has Room To Run
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing customized care in Q1. Monthly online revenue per subscriber rose 50% YoY to $84, driven by high adoption of tailored daily treatments.
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
Hims & Hers: Outsized Subscription Growth Is Enviable - Premium Valuations
The bulls have well defended Hims & Hers' recovery from the April 2025 bottom (near to our fair value estimates), thanks to the growing adoption of its personalized healthcare offerings. These have directly triggered the growing subscriber base/ Revenue per Average Subscriber, with the improved manufacturing/ operating scale contributing to the richer profit margins. This is significantly aided by the growing GLP-1 partnership and the regulatory exemption surrounding compounding personalization, lending support to the raised FY2025 guidance and ambitious 2030 targets.
2 Reasons To Double Down On Hims & Hers Ahead Of August
I expected Hims & Hers' stock to break $50, and now I'm buckling up for another rally, with EMAs stacked bullishly at the moment. The company's partnership with Novo Nordisk and the ZAVA acquisition for European expansion should drive the next leg of growth. Wegovy sales and potential cheaper Ozempic offerings are set to boost revenue, with subscriber growth and ARPU at record highs despite macro headwinds.
Hims & Hers: An Excellent Subscription Business
Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easily outpacing its competition. The trend among millenials and Gen Z patients towards digital health should ensure Hims sustaining its pole position.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market
Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA's established infrastructure and regulatory expertise across four major European countries. Hims' proven GLP-1 strategy in the U.S. positions it to address Europe's unmet demand for affordable, personalized weight-loss solutions via telehealth.
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
